Open AccessSAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
Author(s) -
Mônica R. Gadelha,
Annamaria Colao,
Marie Bex,
Federico Campigotto,
Amy Bartalotta,
Ricardo Maamari,
Gérald Raverot
Publication year - 2019
Publication title -
journal of the endocrine society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.046
H-Index - 20
ISSN - 2472-1972
DOI - 10.1210/js.2019-sat-433
Subject(s) - pasireotide , acromegaly , lanreotide , medicine , tolerability , octreotide , somatostatin , refractory (planetary science) , open label study , clinical endpoint , gastroenterology , urology , surgery , adverse effect , clinical trial , growth hormone , hormone , physics , astrobiology